GREENBERG LON R sold $411K of COR

GREENBERG LON R sold 1,280 shares of Cencora, Inc. (COR) at $321.30 ($0.41M total) on 2026-09-16.

Original reporting
SEC EDGAR · GREENBERG LON R
Published Sep 17, 2026, 7:58 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 8:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$COR
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

Low
01

Why it matters

The director's sale reduces insider ownership, which some investors view as a bearish indicator, though the size is modest relative to total shares outstanding.

02

Market read

Primary insider sale provides new data for traders monitoring insider activity; limited broader market impact.

03

What to watch

No accompanying earnings or strategic news; the director may be diversifying personal holdings.

Relevance 4/10Novelty 5/10Timing: sale reported on 2026-09-16 (filing date 2026-09-17)

Background

SEC Form 4 filings disclose insider transactions; they are primary sources for insider activity.

Market effects

Minimal impact on the pharmaceutical distribution sector; insider activity is company‑specific.

No broader regional effect; confined to U.S. equity markets.

Limited global relevance.

Counterpoint

The sale could be a routine liquidity event rather than a negative signal.

Key entities

  • Cencora, Inc.

    U.S. pharmaceutical distribution company (ticker CNC).

  • GREENBERG LON R

    Director of Cencora who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

HighAI 9/10

Cencora Agrees to Take Controlling Stake in American Oncology Network in $2.4 Billion Deal Spanning 21 States

Cencora agreed to acquire American Oncology Network (AON) for $2.4 billion, expanding its oncology services. The deal, pending approval, includes $2.3 billion at closing plus up to $100 million in contingent value rights. Cencora already owns 4% of AON and aims to increase its stake to 75%. The acquisition is part of a broader trend of drug wholesalers buying cancer practice management companies.

$CORHighAI 9/10

Cencora to buy American Oncology Network in $2.4bn deal

Cencora (COR) agreed to acquire American Oncology Network (AON) for $2.4bn, including $2.3bn at closing and up to $100m in contingent value rights. COR shares fell 4.84% post-announcement, despite recent gains. The deal expands COR's oncology services into 12 new states. COR raised its fiscal 2026 EPS guidance to at least $17.90. The transaction requires regulatory approval and AON stockholder approval.

$CORHighAI 9/10

Cencora, Inc. (COR): Results of Operations and Financial Condition

Cencora, Inc. (COR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CENCORA TO ACQUIRE AMERICAN ONCOLOGY NETWORK TO STRENGTHEN SUPPORT OF COMMUNITY ONCOLOGY Builds on Cencora’s MSO platform by adding complementary capabilities and expanding presence across twelve additional states CONSHOHOCKEN, PA & FORT MYERS, Fla., October 21, 2026

$CORHighAI 9/10

Cencora to acquire American Oncology Network for $2.4 billion

Cencora Inc. (NYSE:COR) will acquire American Oncology Network Inc. (OTCQX:AONC) for $2.4 billion, including $2.3 billion at closing and up to $100 million in contingent value rights. The deal will expand Cencora's oncology services platform. Cencora expects the acquisition to be accretive to earnings per share by the second year post-closing and updated its 2026 EPS guidance to at least $17.90. The transaction is subject to regulatory approvals and AON stockholder approvals.

$CORHighAI 9/10

Cencora, Inc. (COR) to Acquire American Oncology Network for $2.4B EV

Cencora (COR) agreed to acquire American Oncology Network for $2.4B EV, with $2.3B paid at closing and up to $100M in contingent value rights. Cencora expects to pay about $1.7B for 75% ownership if 25% equity is rolled. The deal is expected to be EPS accretive in year two, subject to approvals. According to Cencora, the acquisition aligns with its strategy to expand in oncology services.

HighAI 8/10

Cancer-practice support would expand to 12 more states under Cencora's planned acquisition

Cencora plans to acquire American Oncology Network (AON), expanding its oncology services to 12 more states. The deal aims to enhance care access and support independent practices. Cencora expects the acquisition to be accretive to its adjusted diluted EPS in the second year post-closing. The transaction is subject to regulatory approvals and AON stockholder approvals.